Healio (7/31, Demko) reports, “Clozapine was linked to an 18% lower risk for hospitalization and 27% lower risk for all-cause discontinuation compared with nonclozapine second-generation antipsychotics, despite greater illness severity in patients with schizophrenia receiving clozapine,” researchers concluded. The 63-cohort study meta-analysis also revealed, however, that clozapine use was “associated with a higher risk for cardiometabolic-related outcomes.” The findings were published online July 31 in JAMA Psychiatry. The author of an accompanying editorial observed, “The meta-analysis…supports evidence that clozapine is effective as it is used in the real world.” MD Magazine (7/31, Walter) also covers the study.
Related Links:
— “Clozapine tied to better effectiveness outcomes than other second-generation antipsychotics, “Savannah Demko, Healio, July 31, 2019